Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/45325
Title: Multicenter evaluation of Cystatin C measurement after assay standardization
Authors: Bargnoux, Anne Sophie
Piéroni, Laurence
Cristol, Jean Paul
Kuster, Nils
Delanaye, Pierre
Carlier, Marie Christine
Fellahi, Soraya
Boutten, Anne
Lombard, Christine
González-Antuña, Ana 
Delatour, Vincent
Cavalier, Etienne
UNESCO Clasification: 32 Ciencias médicas
2403 Bioquímica
Keywords: Cystatin C
Assay Standardization
Issue Date: 2017
Journal: Clinical chemistry (Baltimore, Md.) 
Abstract: Background: Since 2010, a certified reference material ERM-DA471/IFCC has been available for cystatin C (CysC). This study aimed to assess the sources of uncertainty in results for clinical samples measured using standardized assays. Methods: This evaluation was performed in 2015 and involved 7 clinical laboratories located in France and Belgium. CysC was measured in a panel of 4 serum pools using 8 automated assays and a candidate isotope dilution mass spectrometry reference measurement procedure. Sources of uncertainty (imprecision and bias) were evaluated to calculate the relative expanded combined uncertainty for each CysC assay. Uncertainty was judged against the performance specifications derived from the biological variation model. Results: Only Siemens reagents on the Siemens systems and, to a lesser extent, DiaSys reagents on the Cobas system, provided results that met the minimum performance criterion calculated according to the intraindividual and interindividual biological variations. Although the imprecision was acceptable for almost all assays, an increase in the bias with concentration was observed for Gentian reagents, and unacceptably high biases were observed for Abbott and Roche reagents on their own systems. Conclusions: This comprehensive picture of the market situation since the release of ERM-DA471/IFCC shows that bias remains the major component of the combined uncertainty because of possible problems associated with the implementation of traceability. Although some manufacturers have clearly improved their calibration protocols relative to ERM-DA471, most of them failed to meet the criteria for acceptable CysC measurements.
URI: http://hdl.handle.net/10553/45325
ISSN: 0009-9147
DOI: 10.1373/clinchem.2016.264325
Source: Clinical Chemistry [ISSN 0009-9147], v. 63, p. 833-841
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

33
checked on Jul 25, 2021

Page view(s)

7
checked on Jul 10, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.